知镜 Cognispect · 医学文献与研究工作台

Recognizing Euglycemic Diabetic Ketoacidosis in the Era of SGLT2 Inhibitors: A Case Report.

Serrano Reyes JC, Carrillo MF, Jaen RL, Batista AJ.
Cureus · 2026-08-13 · PMID 42732326

文献摘要

Euglycemic diabetic ketoacidosis (euDKA) is an increasingly recognized complication associated with SGLT2 inhibitors. Because serum glucose levels may remain normal or only mildly elevated, diagnosis can be delayed, potentially increasing morbidity. We present the case of a 51-year-old male with long-standing poorly controlled type 2 diabetes mellitus who developed euDKA shortly after initiation of empagliflozin/metformin therapy. The patient presented with generalized weakness, gastrointestinal symptoms, reduced oral intake, polyuria, polydipsia, and weight loss. Initial laboratory evaluation revealed high anion gap metabolic acidosis with positive urinary ketones and a glucose level of 160 mg/dL. Infectious workup was negative. The patient required intensive care management with intravenous fluids, insulin infusion, electrolyte monitoring, and dextrose-containing fluids, with subsequent complete resolution of metabolic abnormalities. This case adds to the growing body of literature describing euDKA in patients receiving SGLT2 inhibitor therapy in the setting of reduced oral intake and poorly controlled diabetes mellitus.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。